Small-cell lung cancer and immunochemotherapy withPropionibacterium granulosum KP 45
- 20 Downloads
Seventy-nine patients with small-cell lung cancer were treated with vincristin, methotrexate, and cyclophosphamide in inductive therapy and with methotrexate, cyclophosphamide, and procarbazine in maintenance therapy. Patients were divided at random into two groups: one group received chemotherapy alone and the second group was additionally subjected to systemic immunotherapy withPropionibacterium granulosum strain KP-45. In general, differences in the frequency of therapy response and in duration of remission could not be stated between the two groups of patients, but patients responding to chemotherapy showed a significantly longer remission time and lower complication rates. This benificial effect of chemoimmunotherapy is not related to a direct antitumor activity of the immunomodifier used, but to the lowered risk of myelosuppression and infections. Immunomodulation in combination with chemo- and/or radiotherapy can be recommended for the treatment of small-cell lung cancer.
Key wordsSmall-cell lung cancer Systemic immunotherapy Propionibacterium granulosum Immunochemotherapy
Unable to display preview. Download preview PDF.
- Adlam C, Broughton ES, Scott MT (1972) Enhanced resistance of mice to infection with bacteria following pretreatment with Corynebacterium parvum. Nature 235:219–220Google Scholar
- Cerutti I (1975) Antiviral properties of Corynebacterium parvum. In: Corynebacterium parvum — Application in experimental and clinical oncology. Plenum Press, New York, pp 84–90Google Scholar
- Chare MJB, Baum M (1978) The effect of Corynebacterium parvum on proliferation of monocyte precursors in the bone marrow in mice. Dev Biol Stand 38:195–200Google Scholar
- Halpern BN, Prevot AR, Biozzi G, Stiffel G, Mouton D, Morard JC, Bouthilleir Y, Decreusfound C (1964) Stimulation de l'activité phagocytaire du systéme reticuloendothelial provoquée par Corynebacterium parvum. Res J Rethiculoendothel Soc 1:77–96Google Scholar
- Israel L (1975) Report of 414 cases of human tumours treated with corynebacteria. In: Corynebacterium parvum — Application in experimental and clinical oncology. Plenum Press, New York, pp 389–401Google Scholar
- Nathanson L (1977) Immunology and immunotherapy of human breast cancer. Cancer Immunol Immunother 2:209–224Google Scholar
- Pinsky C, De Jager R, Wittes R (1977) Corynebacterium parvum as adjuvant to combination chemotherapy in patients with advanced breast cancer. In: Neoplasm immunity: Solid tumor therapy. The Franklin Institute Press, Philadelphia, pp 145–151Google Scholar
- Roszkowski W, Szmigielski S, Ko HL, Janiak M, Wrembel K, Pulverer G, Jeljaszewicz J (1980) Effect of three strains of Propionibacteria (P. granulosum, P. avidum, P. acnes) and cell wall preparation on lymphocytes and macrophages. Zentralbl Bakteriol (Orig A) 246:393–404Google Scholar
- Roszkowski K, Roszkowski W, Ko HL, Szmigielski S, Pulverer G, Jeljaszewicz J (1982) Clinical experience in treatment of cancer by propionibacteria. In: Bacteria and cancer. Academic Press, London, New York, pp 331–357Google Scholar
- Szmigielski S, Roszkowski W, Roszkowskii K, Ko HL, Jeljaszewicz J, Pulverer G (1982) Experimental immunostimulation by propionibacteria. In: Bacteria and cancer. Academic Press, London, New York, pp 129–147Google Scholar
- Takita H, Moayeri H (1976) Effects of Corynebacterium parvum and chemotherapy in lung carcinoma. Proc Am Soc Clin Oncol 17:292Google Scholar